A Long-Term, Open-Label, Study on Schizophrenia

Stopped The decision to stop the trial was based on efficacy results in the overall schizophrenia participant population.

Conditions

• Schizophrenia

Interventions

• DRUG: LY2140023
• DRUG: Olanzapine
• DRUG: Aripiprazole
• DRUG: Risperidone
• DRUG: Quetiapine

Sponsor

Eli Lilly and Company